Grand Pharmaceutical Group Ltd
HKEX:512
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.28
5.62
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Grand Pharmaceutical Group Ltd
Total Equity
Grand Pharmaceutical Group Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Total Equity
HK$15.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
33%
|
|
|
S
|
SSY Group Ltd
HKEX:2005
|
Total Equity
HK$7.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Total Equity
¥13.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
16%
|
CAGR 10-Years
9%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Total Equity
¥32.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
22%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Total Equity
HK$48.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Total Equity
$740.1m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
Grand Pharmaceutical Group Ltd
Glance View
Grand Pharmaceutical Group Ltd. engages in the development, manufacture and distribution of pharmaceutical products. The firm is principally engaged in manufacturing and sales of pharmaceutical preparations and medical devices, bio-technology products, nutrition products, specialized pharmaceutical raw materials and other products. The main products of the Company cover the anti-tumor, cardiovascular emergency pharmaceutical products and advanced cerebro-cardiovascular intervention advanced medical devices, anti-virus and anti-infection, respiratory and ear-nose-throat (ENT), bio-health products and specialized pharmaceutical ingredients.
See Also
What is Grand Pharmaceutical Group Ltd's Total Equity?
Total Equity
15.7B
HKD
Based on the financial report for Jun 30, 2024, Grand Pharmaceutical Group Ltd's Total Equity amounts to 15.7B HKD.
What is Grand Pharmaceutical Group Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
33%
Over the last year, the Total Equity growth was 9%. The average annual Total Equity growth rates for Grand Pharmaceutical Group Ltd have been 9% over the past three years , 15% over the past five years , and 33% over the past ten years .
You don't have any saved screeners yet
